Koebner's Phenomenon in Psoriasis and Lichen Planus (RENBOEK)
A Prospective Study to Investigate the Pathophysiology of the Koebner's Phenomenon in Psoriasis and Lichen Planus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Marie-Charlotte Brüggen, MD PhD
- Phone Number: +41 44 255 1111
- Email: marie-charlotte.brueggen@usz.ch
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Dermatologist diagnosed psoriasis (group psoriasis), lichen planus (group lichen planus) or no skin disease (group healthy controls)
- Subject is capable of giving informed consent
- Signed informed consent
Exclusion Criteria:
- Use of systemic immunosuppressive/immunmodulating agents in the last three months
- Use of topical anti-inflammatory treatment in the last 7 days in the area of sampling.
- Phototherapy in the last 4 weeks
- Active or recurrent serious bacterial, fungal or viral infection at the time of enrollment by patient history, including patients with Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis.
- Female patients of childbearing potential who are pregnant or breast feeding or planning a pregnancy during the duration of the trial and/or not practicing acceptable birth control for the duration of the trial
- Known or suspected non-compliance, drug or alcohol abuse,
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
- Previous enrolment into the current study,
- Enrolment of the investigator, his/her family members, employees and other dependent persons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tape stripping
|
a small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in the transcriptomic profile comparing psoriasis patients with and without induced koebner phenomenon
Time Frame: Day 0, Day 3 (optional), Day 14 (optional)
|
Transcriptomic profile at all timepoints (reads per 55µm diameter dot)
|
Day 0, Day 3 (optional), Day 14 (optional)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in the proteomic profile comparing psoriasis patients with and without induced koebner phenomenon
Time Frame: Day 0, Day 3 (optional), Day 14 (optional)
|
Olink multiplex proteomics analysis at all timepoints
|
Day 0, Day 3 (optional), Day 14 (optional)
|
|
Characterization of involved immune cells in the skin comparing psoriasis patients with and without induced koebner phenomenon
Time Frame: Day 0, Day 3 (optional), Day 14 (optional)
|
Imaging mass cytometry (skin biopsies) at all timepoints
|
Day 0, Day 3 (optional), Day 14 (optional)
|
|
Characterization of skin mikrobiome
Time Frame: Day 0, Day 3, Day 14
|
Skin swabs at all timepoints, analyzed by isolation and sequencing of the microbial DNA
|
Day 0, Day 3, Day 14
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marie-Charlotte Brüggen, MD PhD, University of Zurich
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-00427
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.